# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 11, "Clin Ther .", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasJournal> \"Clin Ther .\"."
1, PublicationYear, 12, 16, "2008", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasPublicationYear> \"2008\"."
160, Title, 99, 344, "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasTitle> \"A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .\"."
2, Duration, 101, 110, "52 - week", "", 
153, Multicenter, 113, 126, "multinational", "", 
3, OpenLabel, 129, 141, "open - label", "", 
4, Parallel, 144, 160, "parallel - group", "", 
5, CTDesign, 163, 177, "noninferiority", "", 
6, CTDesign, 180, 199, "treat - to - target", "", 
7, InsulinDetemir, 216, 231, "insulin detemir", "", 
8, InsulinGlargine, 237, 253, "insulin glargine", "", 
9, RelativeTime, 286, 294, "mealtime", "", 
10, InsulinAspart, 295, 309, "insulin aspart", "", 
11, Type2Diabetes, 327, 342, "type 2 diabetes", "", 
12, Author, 345, 356, "Hollander P", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasAuthor> \"Hollander P\"."
13, Author, 365, 373, "Cooper J", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasAuthor> \"Cooper J\"."
14, Author, 376, 388, "Bregnh ø j J", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasAuthor> \"Bregnh ø j J\"."
15, Author, 391, 402, "Pedersen CB", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasAuthor> \"Pedersen CB\"."
16, USA, 477, 480, "USA", "", "<http://ctro/data#Population_59569> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
28, ObjectiveDescription, 653, 809, "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasObjectiveDescription> \"This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen\"."
17, Insulin, 713, 720, "insulin", "", 
18, InsulinDetemir, 731, 738, "detemir", "", 
19, InsulinGlargine, 743, 751, "glargine", "", 
52521, Insulin, 765, 772, "insulin", "", 
314, ObjectiveDescription, 810, 955, "in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasObjectiveDescription> \"in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .\"."
27, Precondition, 813, 953, "patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs", "", 
21, Type2Diabetes, 827, 851, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
22, Type2Diabetes, 854, 858, "T2DM", "", 
23, OralAntidiabeticAgent, 889, 912, "oral antidiabetic drugs", "", 
24, OralAntidiabeticAgent, 915, 919, "OADs", "", 
26, Insulin, 925, 932, "insulin", "", 
25, OralAntidiabeticAgent, 949, 953, "OADs", "", 
174, Multicenter, 977, 990, "multinational", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
29, Duration, 993, 1002, "52 - week", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTduration> \"52 - week\"."
30, OpenLabel, 1005, 1014, "openlabel", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTDesign> <http://ctro/data#OpenLabel>."
31, Parallel, 1017, 1033, "parallel - group", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
32, CTDesign, 1036, 1050, "noninferiority", "", "<http://ctro/data#CTDesign_59564> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#CTDesign>. <http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTDesign> <http://ctro/data#CTDesign_59564>."
33, CTDesign, 1053, 1072, "treat - to - target", "", "<http://ctro/data#CTDesign_59565> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#CTDesign>. <http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTDesign> <http://ctro/data#CTDesign_59565>."
42, Precondition, 1081, 1216, "Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months", "", "<http://ctro/data#Population_59569> <http://ctro/data#hasPrecondition> \"Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months\"."
34, Type2Diabetes, 1110, 1114, "T2DM", "", 
35, OralAntidiabeticAgent, 1162, 1165, "OAD", "", 
37, Insulin, 1169, 1176, "insulin", "", 
36, OralAntidiabeticAgent, 1195, 1199, "OADs", "", 
38, Randomized, 1222, 1232, "randomized", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
39, AllocationRatio, 1238, 1243, "2 : 1", "", "<http://ctro/data#AllocationRatio_59534> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_59534>."
40, InsulinDetemir, 1261, 1268, "detemir", "", 
41, InsulinGlargine, 1272, 1280, "glargine", "", 
43, InsulinDetemir, 1320, 1327, "detemir", "", "<http://ctro/data#Medication_59633> <http://ctro/data#hasDrug> <http://ctro/data#InsulinDetemir>."
44, Frequency, 1350, 1369, "once or twice daily", "", "<http://ctro/data#Intervention_59621> <http://ctro/data#hasFrequency> \"once or twice daily\"."
45, InsulinGlargine, 1376, 1384, "glargine", "", "<http://ctro/data#Medication_59640> <http://ctro/data#hasDrug> <http://ctro/data#InsulinGlargine>."
46, Frequency, 1402, 1412, "once daily", "", "<http://ctro/data#Intervention_59627> <http://ctro/data#hasFrequency> \"once daily\"."
47, InsulinAspart, 1415, 1429, "Insulin aspart", "", 
52522, RelativeTime, 1443, 1452, "mealtimes", "", 
49, Insulin, 1455, 1462, "Insulin", "", 
50, OralAntidiabeticAgent, 1556, 1560, "OADs", "", 
51, InsulinDetemir, 1587, 1594, "detemir", "", 
52, InsulinGlargine, 1599, 1607, "glargine", "", 
52525, DoseDescription, 1608, 1749, "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L", "", "<http://ctro/data#Medication_59633> <http://ctro/data#hasDoseDescription> \"were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L\". <http://ctro/data#Medication_59640> <http://ctro/data#hasDoseDescription> \"were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L\"."
52524, RelativeTime, 1635, 1647, "prebreakfast", "", 
52523, RelativeTime, 1654, 1663, "predinner", "", 
55, InsulinDetemir, 1668, 1675, "detemir", "", 
56, Frequency, 1689, 1700, "twice daily", "", 
57, FastingPlasmaGlucose_target, 1703, 1749, "plasma glucose target of < or = 6 . 0 mmol / L", "", 
200, Millimoles_per_litre, 1741, 1749, "mmol / L", "", 
316, PlasmaGlucose, 1777, 1791, "plasma glucose", "", 
58, Insulin, 1893, 1900, "insulin", "", 
317, PlasmaGlucose, 1977, 1991, "plasma glucose", "", 
318, PlasmaGlucose, 1994, 1998, "SMPG", "", 
202, TimePoint, 2004, 2012, "baseline", "", 
203, TimePoint, 2017, 2025, "after 24", "", 
204, TimePoint, 2030, 2038, "52 weeks", "", 
59, HbA1c, 2076, 2099, "glycosylated hemoglobin", "", 
60, HbA1c, 2102, 2112, "HbA ( 1c )", "", 
206, TimePoint, 2118, 2126, "52 weeks", "", 
62, FastingPlasmaGlucose, 2179, 2201, "fasting plasma glucose", "", 
63, FastingPlasmaGlucose, 2204, 2207, "FPG", "", 
319, PostprandialPlasmaGlucose, 2212, 2239, "postprandial plasma glucose", "", 
320, InsulinDose, 2242, 2255, "insulin doses", "", 
64, BodyWeight, 2262, 2268, "weight", "", 
211, TimePoint, 2279, 2287, "52 weeks", "", 
65, Hypoglycemia, 2334, 2346, "hypoglycemia", "", 
66, EndPointDescription, 2351, 2365, "adverse events", "", 
67, EndPointDescription, 2368, 2371, "AEs", "", 
68, IntentionToTreat, 2390, 2412, "intention - to - treat", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasAnalysisApproach> <http://ctro/data#IntentionToTreat>."
69, NumberPatientsCT, 2433, 2436, "319", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasNumberPatientsCT> \"319\"."
70, Male, 2448, 2456, "58 . 0 %", "", "<http://ctro/data#Population_59569> <http://ctro/data#hasGender> <http://ctro/data#Male>."
71, Female, 2464, 2472, "42 . 0 %", "", "<http://ctro/data#Population_59569> <http://ctro/data#hasGender> <http://ctro/data#Female>."
72, Ethnicity, 2482, 2496, "78 . 4 % white", "", "<http://ctro/data#Ethnicity_59571> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_59569> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_59571>."
218, Mean, 2499, 2503, "mean", "", 
73, AvgAge, 2510, 2512, "58", "", "<http://ctro/data#Population_59569> <http://ctro/data#hasAvgAge> \"58\"."
216, Year, 2513, 2518, "years", "", 
217, Mean, 2521, 2525, "mean", "", 
74, BodyWeight, 2526, 2532, "weight", "", 
75, Kg, 2542, 2544, "kg", "", 
219, Mean, 2547, 2551, "mean", "", 
102224, Duration, 2575, 2587, "13 . 6 years", "", 
322, TimePoint, 2595, 2606, "study entry", "", 
226, OralAntidiabeticAgent, 2666, 2669, "OAD", "", 
228, OralAntidiabeticAgent, 2746, 2749, "OAD", "", 
230, TimePoint, 2760, 2768, "52 weeks", "", "<http://ctro/data#Outcome_59647> <http://ctro/data#hasTimePoint> \"52 weeks\". <http://ctro/data#Outcome_59674> <http://ctro/data#hasTimePoint> \"52 weeks\"."
84, InsulinDetemir, 2815, 2822, "detemir", "", 
85, InsulinGlargine, 2827, 2835, "glargine", "", 
240, Mean, 2848, 2852, "mean", "", "<http://ctro/data#Mean_59580> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_59578> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_59580>."
86, HbA1c, 2853, 2863, "HbA ( 1c )", "", "<http://ctro/data#Endpoint_59578> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
89, ResultMeasuredValue, 2866, 2872, "7 . 19", "", "<http://ctro/data#Outcome_59647> <http://ctro/data#hasResultMeasuredValue> \"7 . 19\"."
91, Percentage, 2873, 2874, "%", "", "<http://ctro/data#Endpoint_59578> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
90, ResultMeasuredValue, 2879, 2885, "7 . 03", "", "<http://ctro/data#Outcome_59674> <http://ctro/data#hasResultMeasuredValue> \"7 . 03\"."
92, Percentage, 2886, 2887, "%", "", 
241, Mean, 2905, 2909, "mean", "", 
88, DiffGroupAbsValue, 2923, 2929, "0 . 17", "", "<http://ctro/data#DiffBetweenGroups_59701> <http://ctro/data#hasDiffGroupAbsValue> \"0 . 17\"."
93, Percentage, 2930, 2931, "%", "", 
87, ConfIntervalDiff, 2934, 2962, "95 % CI , - 0 . 07 to 0 . 40", "", "<http://ctro/data#DiffBetweenGroups_59701> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 0 . 07 to 0 . 40\"."
242, Mean, 2974, 2978, "mean", "", 
96, HbA1c, 2991, 2996, "HbAlc", "", 
323, TimePoint, 3002, 3010, "baseline", "", 
97, Reduction, 3015, 3021, "1 . 52", "", "<http://ctro/data#Outcome_59647> <http://ctro/data#hasChangeValue> \"1 . 52\"."
94, Percentage, 3022, 3023, "%", "", 
98, Reduction, 3030, 3036, "1 . 68", "", "<http://ctro/data#Outcome_59674> <http://ctro/data#hasChangeValue> \"1 . 68\"."
95, Percentage, 3037, 3038, "%", "", 
99, HbA1c, 3060, 3070, "HbA ( 1c )", "", 
100, InsulinDetemir, 3113, 3120, "detemir", "", 
101, Frequency, 3138, 3157, "once or twice daily", "", 
52526, Mean, 3225, 3229, "mean", "", "<http://ctro/data#Mean_59585> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_59583> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_59585>."
102, FastingPlasmaGlucose, 3230, 3233, "FPG", "", "<http://ctro/data#Endpoint_59583> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
104, ResultMeasuredValue, 3236, 3242, "7 . 05", "", "<http://ctro/data#Outcome_59710> <http://ctro/data#hasResultMeasuredValue> \"7 . 05\"."
105, ResultMeasuredValue, 3247, 3253, "6 . 68", "", "<http://ctro/data#Outcome_59737> <http://ctro/data#hasResultMeasuredValue> \"6 . 68\"."
106, Millimoles_per_litre, 3254, 3262, "mmol / L", "", "<http://ctro/data#Endpoint_59583> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
52527, Mean, 3272, 3276, "mean", "", 
103, FastingPlasmaGlucose, 3287, 3290, "FPG", "", 
333, TimePoint, 3296, 3304, "baseline", "", 
109, Reduction, 3309, 3315, "2 . 56", "", "<http://ctro/data#Outcome_59710> <http://ctro/data#hasChangeValue> \"2 . 56\"."
108, Reduction, 3322, 3328, "2 . 92", "", "<http://ctro/data#Outcome_59737> <http://ctro/data#hasChangeValue> \"2 . 92\"."
107, Millimoles_per_litre, 3329, 3337, "mmol / L", "", 
263, Mean, 3340, 3344, "mean", "", 
110, DiffGroupAbsValue, 3358, 3364, "0 . 36", "", "<http://ctro/data#DiffBetweenGroups_59764> <http://ctro/data#hasDiffGroupAbsValue> \"0 . 36\"."
111, ConfIntervalDiff, 3367, 3395, "95 % CI , - 0 . 26 to 0 . 99", "", "<http://ctro/data#DiffBetweenGroups_59764> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 0 . 26 to 0 . 99\"."
267, Mean, 3499, 3503, "Mean", "", "<http://ctro/data#Mean_59590> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_59588> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_59590>."
268, WeightGain, 3504, 3515, "weight gain", "", "<http://ctro/data#Endpoint_59588> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#WeightGain>."
269, TimePoint, 3519, 3527, "52 weeks", "", "<http://ctro/data#Outcome_59773> <http://ctro/data#hasTimePoint> \"52 weeks\". <http://ctro/data#Outcome_59800> <http://ctro/data#hasTimePoint> \"52 weeks\"."
115, InsulinDetemir, 3557, 3564, "detemir", "", 
116, InsulinGlargine, 3575, 3583, "glargine", "", 
272, ResultMeasuredValue, 3586, 3591, "2 . 8", "", "<http://ctro/data#Outcome_59773> <http://ctro/data#hasResultMeasuredValue> \"2 . 8\"."
273, ResultMeasuredValue, 3595, 3600, "3 . 8", "", "<http://ctro/data#Outcome_59800> <http://ctro/data#hasResultMeasuredValue> \"3 . 8\"."
119, Kg, 3601, 3603, "kg", "", "<http://ctro/data#Endpoint_59588> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
275, Mean, 3606, 3610, "mean", "", 
120, DiffGroupAbsValue, 3624, 3632, "- 1 . 04", "", "<http://ctro/data#DiffBetweenGroups_59827> <http://ctro/data#hasDiffGroupAbsValue> \"- 1 . 04\"."
121, ConfIntervalDiff, 3635, 3665, "95 % CI , - 2 . 08 to - 0 . 01", "", "<http://ctro/data#DiffBetweenGroups_59827> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 2 . 08 to - 0 . 01\"."
122, PvalueDiff, 3668, 3678, "P < 0 . 05", "", "<http://ctro/data#DiffBetweenGroups_59827> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 2 . 08 to - 0 . 01\"."
334, TimePoint, 3723, 3743, "the end of the study", "", 
125, Hypoglycemia, 3800, 3812, "hypoglycemic", "", "<http://ctro/data#Endpoint_59593> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
124, PercentageAffected, 3839, 3844, "4 . 7", "", "<http://ctro/data#Outcome_59836> <http://ctro/data#hasPercentageAffected> \"4 . 7\"."
123, PercentageAffected, 3851, 3856, "5 . 7", "", "<http://ctro/data#Outcome_59863> <http://ctro/data#hasPercentageAffected> \"5 . 7\"."
328, ObservedResult, 3908, 3988, "There was no significant difference in the risk of hypoglycemia between groups .", "", "<http://ctro/data#Outcome_59836> <http://ctro/data#hasObservedResult> \"There was no significant difference in the risk of hypoglycemia between groups .\". <http://ctro/data#Outcome_59863> <http://ctro/data#hasObservedResult> \"There was no significant difference in the risk of hypoglycemia between groups .\"."
126, Hypoglycemia, 3959, 3971, "hypoglycemia", "", 
127, EndPointDescription, 4021, 4024, "AEs", "", "<http://ctro/data#EndPointDescription_59599> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_59598> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_59599>."
128, EndPointDescription, 4043, 4046, "AEs", "", 
129, NumberAffected, 4092, 4095, "185", "", "<http://ctro/data#Outcome_59890> <http://ctro/data#hasNumberAffected> \"185\"."
131, NumberPatientsArm, 4098, 4101, "214", "", "<http://ctro/data#Arm_59603> <http://ctro/data#hasNumberPatientsArm> \"214\"."
133, PercentageAffected, 4113, 4119, "86 . 4", "", "<http://ctro/data#Outcome_59890> <http://ctro/data#hasPercentageAffected> \"86 . 4\"."
135, EndPointDescription, 4138, 4141, "AEs", "", 
130, NumberAffected, 4146, 4148, "88", "", "<http://ctro/data#Outcome_59917> <http://ctro/data#hasNumberAffected> \"88\"."
132, NumberPatientsArm, 4151, 4154, "105", "", "<http://ctro/data#Arm_59612> <http://ctro/data#hasNumberPatientsArm> \"105\"."
134, PercentageAffected, 4166, 4172, "83 . 8", "", "<http://ctro/data#Outcome_59917> <http://ctro/data#hasPercentageAffected> \"83 . 8\"."
136, EndPointDescription, 4191, 4194, "AEs", "", 
304, ConclusionComment, 4213, 4439, "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasConclusionComment> \"when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .\"."
139, Type2Diabetes, 4288, 4292, "T2DM", "", 
140, Insulin, 4327, 4334, "insulin", "", 
299, OralAntidiabeticAgent, 4344, 4347, "OAD", "", 
142, InsulinDetemir, 4359, 4366, "detemir", "", 
143, InsulinGlargine, 4386, 4394, "glargine", "", 
306, ConclusionComment, 4440, 4530, "Both basal insulins were associated with clinically relevant reductions in hyperglycemia .", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasConclusionComment> \"Both basal insulins were associated with clinically relevant reductions in hyperglycemia .\"."
145, Insulin, 4451, 4459, "insulins", "", 
146, Hypoglycemia, 4515, 4528, "hyperglycemia", "", 
307, ConclusionComment, 4531, 4630, "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .", "", "<http://ctro/data#ClinicalTrial_59529> <http://ctro/data#hasConclusionComment> \"Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .\"."
147, Hypoglycemia, 4609, 4621, "hypoglycemia", "", 
148, EndPointDescription, 4625, 4628, "AEs", "", 
149, PMID, 4688, 4696, "19108786", "", "<http://ctro/data#Publication_59519> <http://ctro/data#hasPMID> \"19108786\"."
